Selected article for: "evidence disseminate and guideline development process"
Author: Patricia Rios; Amruta Radhakrishnan; Sonia M. Thomas; Nazia Darvesh; Sharon E. Straus; Andrea C. Tricco
Title: Guidelines for preventing respiratory illness in older adults aged 60 years and above living in long-term care: A rapid review of clinical practice guidelines
  • Document date: 2020_3_26
    • ID: kwncu3ji_271
    Snippet: ☐Information/description of the cost information that emerged from the inquiry (e.g., specific drug acquisition costs per treatment course) ☐How the information gathered was used to inform the guideline development process and/or formation of the recommendations 21. MONITORING/ AUDITING CRITERIA Provide monitoring and/or auditing criteria to measure the application of guideline recommendations. ☐Purpose and intent of the external review (e......
    Document: ☐Information/description of the cost information that emerged from the inquiry (e.g., specific drug acquisition costs per treatment course) ☐How the information gathered was used to inform the guideline development process and/or formation of the recommendations 21. MONITORING/ AUDITING CRITERIA Provide monitoring and/or auditing criteria to measure the application of guideline recommendations. ☐Purpose and intent of the external review (e.g., to improve quality, gather feedback on draft recommendations, assess applicability and feasibility, disseminate evidence) ☐Methods taken to undertake the external review (e.g., rating scale, open-ended questions)

    Search related documents:
    Co phrase search for related documents
    • auditing CRITERIA and drug acquisition: 1, 2, 3, 4, 5, 6, 7, 8
    • auditing CRITERIA and drug acquisition cost: 1, 2, 3, 4, 5, 6, 7, 8
    • auditing CRITERIA and guideline development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • auditing CRITERIA and guideline development process: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • cost information and drug acquisition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cost information and drug acquisition cost: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cost information and guideline development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cost information and guideline development process: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cost information and information gather: 1, 2, 3, 4
    • drug acquisition and guideline development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • drug acquisition and guideline development process: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • drug acquisition cost and guideline development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • drug acquisition cost and guideline development process: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • evidence disseminate and feasibility applicability: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • evidence disseminate and feasibility applicability assess: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • evidence disseminate and feedback gather: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • evidence disseminate and guideline development: 1, 2
    • evidence disseminate and guideline development process: 1, 2
    • evidence disseminate and information gather: 1